Meta analysis of atorvastatin combined with trimetazidine in the treatment of angina pectoris of coronary heart disease

Abstract

Objective To evaluate efficacy and safety of Atorvastatin combined with trimetazidine Sibutramine treating angina pectoris of coronary heart disease. Methods Of computer retrieval China National Knowledge Infrastructure (CNKI), Wanfang database, VIP database and search atorvastatin statins combined with trimetazidine trimetazidine in the treatment of angina pectoris of coronary heart disease: a randomized controlled trial, according to Jadad scale to evaluate the quality of the included studies and extracted data. Meta analysis was performed using RevMan 5.3. Results In accordance with the inclusion criteria were included in the 18 study, a total of 1 848 patients. The software of RevMan 5.3 on cardiovascular events incidence, clinical curative effect, angina pectoris, blood lipid [total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C), high density lipoprotein cholesterol (HDL-C)], the improvement of cardiac function [including cardiac index left ventricular end diastolic diameter (LVEDD), left ventricular end systolic diameter (LVESD)] and the adverse reactions of meta analysis showed that compared with pure atorvastatin, atorvastatin combined with trimetazidine can reduce the incidence of cardiovascular events [OR=0.19, 95% Cl (0.11, 0.35), P<0.01], reduce seizure frequency and duration of angina [WMD=-1.52, 95% CI (-1.84, -0.99), P<0.01; WMD=-1.80, 95% CI (-2.20, -1.50), P<0.01], improve the clinical efficiency of [OR=4.78, 95% Cl (3.54, 6.47), P<0.01] display. Blood lipid and cardiac ultrasound index show that atorvastatin combined with trimetazidine can better improve the patient′s LVEDD [WMD=-2.69, 95% CI (-4.39, -0.98), P<0.01] LVESD [WMD=-6.92, 95% CI(-11.82, -2.02), P<0.01]. The decrease of serum level of TC, TG , LDL-C was better than atorvastatin monotherapy, but there were no statistically significant differences in the improvement level of serum HDL-C in the included patients (P=0.17). In the included studies, atorvastatin combined with trimetazidine can effectively reduce the incidence of adverse reactions in patients [OR=0.33, 95% CI (0.13, 0.85), P=0.02]. Conclusions Atorvastatin combined with trimetazidine is safer and more effective than atorvastatin alone in the treatment of coronary heart disease angina pectoris. Key words: Atorvastatin; Trimetazidine; Coronary disease; Angina pectoris; Meta-analysis